A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Inclusion Criteria: Donor: * Donor eligibility will be determined according to applicable federal, state and local regulations and institutional standards * 18-65 years of age * 6/6 HLA-matched sibling * Fulfill individual Transplant Center criteria to serve as a mobilized blood cell donor * Serum creatinine \<2.0mg/dl Recipient: * 18 to 65 years of age * 6/6 HLA antigen matched sibling willing to donate PBSC for transplant * Fulfill individual Transplant Center Criteria for transplant * One of the following diagnoses: * Acute myelogenous leukemia (AML) in 1st remission or beyond with \<5% marrow blasts and no circulating blasts. Marrow must be done within 30 days of the start of transplant conditioning regimen in alignment with other pre-transplant assessments. * Acute lymphoblastic leukemia (ALL) in 1st remission or beyond with \<5% marrow blasts and no circulating blasts * Myelodysplastic syndrome, either intermediate-1,2, or high risk by International Prognostic Scoring System or transfusion dependent * Chronic myelogenous leukemia (CML) failing or intolerant to tyrosine kinase inhibitor based therapy * Non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) in 2nd or greater complete remission, partial remission, or in relapse (but with at least stable disease after most recent therapy) * Chronic lymphocytic leukemia (CLL), relapsing after at least one prior regimen, or in remission with 17p deletion * Serum creatinine must be \<2.0mg/dl * Total bilirubin…